- Home
- NVGS vs COLL Comparison
NVGS vs COLL Comparison
Compare NVGS & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVGS
- COLL
- Stock Information
- Founded
- NVGS 1997
- COLL 2002
- Country
- NVGS United Kingdom
- COLL United States
- Employees
- NVGS N/A
- COLL N/A
- Industry
- NVGS Marine Transportation
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- NVGS Consumer Discretionary
- COLL Health Care
- Exchange
- NVGS Nasdaq
- COLL Nasdaq
- Market Cap
- NVGS 957.8M
- COLL 910.2M
- IPO Year
- NVGS N/A
- COLL 2015
- Fundamental
- Price
- NVGS $10.76
- COLL $28.07
- Analyst Decision
- NVGS Strong Buy
- COLL Strong Buy
- Analyst Count
- NVGS 3
- COLL 5
- Target Price
- NVGS $22.00
- COLL $43.60
- AVG Volume (30 Days)
- NVGS 271.4K
- COLL 438.9K
- Earning Date
- NVGS 05-14-2025
- COLL 05-08-2025
- Dividend Yield
- NVGS 1.64%
- COLL N/A
- EPS Growth
- NVGS 8.18
- COLL 43.56
- EPS
- NVGS 1.19
- COLL 1.86
- Revenue
- NVGS $566,679,000.00
- COLL $631,449,000.00
- Revenue This Year
- NVGS $5.93
- COLL $20.00
- Revenue Next Year
- NVGS N/A
- COLL $3.93
- P/E Ratio
- NVGS $11.11
- COLL $15.63
- Revenue Growth
- NVGS 2.90
- COLL 11.41
- 52 Week Low
- NVGS $12.23
- COLL $27.28
- 52 Week High
- NVGS $18.18
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- NVGS 11.71
- COLL 37.90
- Support Level
- NVGS $13.15
- COLL $29.01
- Resistance Level
- NVGS $14.47
- COLL $30.53
- Average True Range (ATR)
- NVGS 0.44
- COLL 0.82
- MACD
- NVGS -0.18
- COLL -0.10
- Stochastic Oscillator
- NVGS 2.91
- COLL 5.73
About NVGS Navigator Holdings Ltd. (Marshall Islands)
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture).
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.